Symptomatic cardiac metastases of breast cancer 27 years after mastectomy: a case report with literature review - pathophysiology of molecular mechanisms and metastatic pathways, clinical aspects, diagnostic procedures and treatment modalities

World Journal of Surgical Oncology

Stjepko Plestina⁶  Antonio Juretic⁶  Fedor Santek⁶  Nora Nikolac⁴  Damir Tentor¹  Ivan Aleric³  Irena Ivanac²  Ranka Stern-Padovan⁵  Darko Katalinic⁶ 

[1] Department of Pathology and Cytology, University Hospital Centre (KBC Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia;Department of Cardiovascular Diseases, University Hospital Centre (KBC Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia;Department of Pulmonary Medicine, University Hospital Centre (KBC Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia;Department of Clinical Chemistry, University Hospital Centre “Sisters of Charity”, University of Zagreb School of Medicine, Zagreb, Croatia;Department of Diagnostic and Interventional Radiology, University Hospital Centre (KBC Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia;Department of Oncology, University Hospital Centre (KBC Zagreb), University of Zagreb School of Medicine, Kispaticeva 12, HR-10000, Zagreb, Croatia

关键词: Treatment;    Symptoms;    Pathophysiology;    Breast cancer;    Heart metastases;   

Others  :  826523
DOI  :  10.1186/1477-7819-11-14

 received in 2012-08-01, accepted in 2013-01-13,  发布年份 2013

【 摘 要 】

Metastases to the heart and pericardium are rare but more common than primary cardiac tumours and are generally associated with a rather poor prognosis. Most cases are clinically silent and are undiagnosed in vivo until the autopsy. We present a female patient with a 27-year-old history of an operated primary breast cancer who was presented with dyspnoea, paroxysmal nocturnal dyspnoea and orthopnoea. The clinical signs and symptoms aroused suspicion of congestive heart failure. However, the cardiac metastases were detected during a routine cardiologic evaluation and confirmed with computed tomography imaging. Additionally, this paper outlines the pathophysiology of molecular and clinical mechanisms involved in the metastatic spreading, clinical presentation, diagnostic procedures and treatment of heart metastases. The present case demonstrates that a complete surgical resection and systemic chemotherapy may result in a favourable outcome for many years. However, a lifelong medical follow-up, with the purpose of a detection of metastases, is highly recommended. We strongly call the attention of clinicians to the fact that during the follow-up of all cancer patients, such heart failure may be a harbinger of the secondary heart involvement.

【 授权许可】

   
2013 Katalinic et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Tedeschi A: Beitrag zum Studium der Herzgeschwiilste. Prag Nmed Wvchnschr 1893, 18:121.
• [2]Reynen K: Frequency of primary tumors of the heart. Am J Cardiol 1996, 77:107.
• [3]Burke A, Virmani R: Tumors of the Cardiovascular System, Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology; 1996.
• [4]Klatt EC, Heitz DR: Cardiac metastases. Cancer 1990, 65:1456-1459.
• [5]Prichard RW: Tumors of the heart. Review of the subject and report of one hundred and fifty cases. Arch Pathol 1951, 51:98-128.
• [6]Chiles C, Woodard PK, Gutierrez FR, Link KM: Metastatic involvement of the heart and pericardium: CT and MR imaging. Radiographics 2000, 20:1073-1103.
• [7]MacGee W: Metastatic and invasive tumours involving the heart in a geriatric population: a necropsy study. Virchows Arch A Pathol Anat Histol 1991, 419:183-189.
• [8]Scott RW, Garvin CF: Tumors of the heart and pericardium. Am Heart J 1939, 17:431-436.
• [9]Bisel HF, Wróblewski F, LaDue JS: Incidence and clinical manifestations of cardiac metastases. JAMA 1953, 153:712-715.
• [10]Young JM, Goldman IR: Tumor metastasis to the heart. Circulation 1954, 9:220-229.
• [11]Lockwood WB, Broghamer WL: The changing prevalence of secondary cardiac neoplasms as related to cancer therapy. Cancer 1980, 45:2659-2662.
• [12]Lam KY, Dickens P, Chan ACL: Tumors of the heart. A 20-year experience with a review of 12485 consecutive autopsies. Arch Pathol Lab Med 1993, 117:1027-1031.
• [13]Virmani R: Tumours metastatic to the heart and pericardium. In Atlas of tumour pathology. Tumours of the heart and great vessels. Edited by Burke A, Virmani R. Washington, DC: AFIP; 1995:195-209. [3rd Series Fascicle 16]
• [14]McAllister HA Jr: Tumours of the heart and pericardium. In Cardiovascular pathology. Volume 2. 2nd edition. Edited by Silver MD. New York, NY: Churchill Livingstone; 1991:1297-1333.
• [15]Wenger NK: Pericardial disease in the elderly. Cardiovasc Clin 1992, 22:97-103.
• [16]Nakayama R, Yoneyama T, Takatani O, Kimura K: A study of metastatic tumors to the heart, pericardium and great vessels. Jpn Heart J 1966, 7:227-234.
• [17]Abraham KP, Reddy V, Gattuso P: Neoplasms metastatic to the heart: review of 3314 consecutive autopsies. Am J Cardiovasc Pathol 1990, 3:195-198.
• [18]Bussani R, De-Giorgio F, Abbate A, Silvestri F: Cardiac metastases. J Clin Pathol 2007, 60:27-34.
• [19]Gibbs P, Cebon JS, Calafiore P, Robinson WA: Cardiac metastases from malignant melanoma. Cancer 1999, 85:78-84.
• [20]Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1889, 1:571-573.
• [21]Ewing J: A treatise of tumors. Philadelphia, PA: Saunders; 1928.
• [22]Suva LJ, Griffin RJ, Makhoul I: Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer 2009, 16:703-713.
• [23]Krug EL, Mjaatvedt CH, Markwald RR: Extracellular matrix from embryonic myocardium elicits an early morphogenetic event in cardiac endothelial differentiation. Dev Biol 1987, 120:348-355.
• [24]Hay ED: An overview of epithelio-mesenchymal transformation. Acta Anat Basel 1995, 154:8-20.
• [25]Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM, Haley JD: A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis 2010, 28:137-155.
• [26]Finger EC, Giaccia AJ: Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 2010, 29:285-293.
• [27]Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA: A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007, 13:7003-7011.
• [28]Margulis A, Zhang W, Alt-Holland A, Crawford HC, Fusenig NE, Garlick JA: E-cadherin suppressionaccelerates squamous cell carcinoma progression in threedimensional, human tissue constructs. Cancer Res 2005, 65:1783-1791.
• [29]Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA: Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008, 68:3645-3654.
• [30]Yilmaz M, Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009, 28:15-33.
• [31]Dumont N, Bakin AV, Arteaga CL: Autocrine transforming growth factor-beta signaling mediates Smadindependent motility in human cancer cells. J Biol Chem 2003, 278:3275-3285.
• [32]Eckert MA, Yang J: Targeting invadopodia to block breast cancer metastasis. Oncotarget 2011, 2:562-568.
• [33]Linder S: The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. Trends Cell Biol 2007, 17:107-117.
• [34]Oxmann D, Held-Feindt J, Stark AM, Hattermann K, Yoneda T, Meintlan R: Endoglin expression in metastatic breast cancer cells enhances their invasive phenotypeEndoglin enhances tumor invasion. Oncogene 2008, 27:3567-3575.
• [35]Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, Shaw JA, Walker RA, Pringle JH, Jones JL: Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 2009, 11:R24. BioMed Central Full Text
• [36]Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, Peretz T, Vlodavsky I, Abramovitch R: Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 2006, 118:1609-1617.
• [37]Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V: Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008, 319:195-198.
• [38]Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, Heikamp E, McDevitt MR, Scheinberg DA, Benezra R, Mittal V: Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 2007, 21:1546-1558.
• [39]Mellick AS, Plummer PN, Nolan DJ, Gao D, Bambino K, Hahn M, Catena R, Turner V, McDonnell K, Benezra R, Brink R, Swarbrick A, Mittal V: Using the transcription factor inhibitior of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth. Cancer Res 2010, 70:7273-7282.
• [40]Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW: Genomic and transcriptionalaberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541.
• [41]Martinez N, Alonso A, Moragues MD, Ponton J, Schneider J: The nuclear pore complex protein Nup88 is overexpressed in tumor cells. Cancer Res 1999, 59:5408-5411.
• [42]Gould VE, Martinez N, Orucevic A, Schneider J, Alonso A: A novel, nuclear pore-associated, widely distributed molecule overexpressed in oncogenesis and development. Am J Pathol 2000, 157:1605-1613.
• [43]Gould VE, Orucevic A, Zentgraf H, Gattuso P, Martinez N, Alonso A: Nup88 (karyoporin) in human malignant neoplasms and dysplasias: Correlations of immunostaining of tissue sections, cytologic smears, and immunoblot analysis. Hum Pathol 2002, 33:536-544.
• [44]Funasaka T, Wong RW: The role of nuclear pore complex in tumor microenvironment and metastasis. Cancer Metastasis Rev 2011, 30:239-251.
• [45]Kline IK: Cardiac lymphatic involvement by metastatic tumor. Cancer 1972, 29:799-808.
• [46]Labib SB, Schick EC, Isner JM: Obstruction of right ventricular outflow tract caused by intracavitary metastatic disease: Analysis of 14 cases. J Am Coll Cardiol 1992, 19:1664-1668.
• [47]Dickens P, Poon CSP, Wat MS: Sudden death associated with solitary intracavitary right atrial metastatic tumour deposit. Forensic Sci Int 1992, 57:169-173.
• [48]Kutalek SP, Panidis IP, Kotler MN, Mintz GS, Carver J, Ross JJ: Metastatic tumors of the heart detected by two-dimensional echocardiography. Am Heart J 1985, 109:343-349.
• [49]Johnson MH, Soulen RL: Echocardiography of cardiac metastases. Am J Roentgenol 1983, 141:677-681.
• [50]Steffens TG, Mayer HS, Das SK: Echocardiographic diagnosis of a right ventricular metastatic tumor. Arch Intern Med 1980, 140:122-123.
• [51]Reynen K, Köckeritz U, Strasser RH: Metastases to the heart. Ann Oncol 2004, 15:375-381.
• [52]Patek PR: The morphology of the lymphatics of the mammalian heart. Am Heart J Anat 1939, 64:203-249.
• [53]Weiss L: Cascade spread of blood-borne metastases in solid and non-solid cancers of humans. In Pulmonary metastasis. Edited by Weiss L, Gilbert H. Boston: Hall; 1978:142-167.
• [54]Dalerba P, Clarke MF: Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Steam Cell 2007, 1:241-242.
• [55]Ferrandina G, Petrillo M, Bonanno G, Scambia G: Targeting CD133 antigen in cancer. Expert Opin Ther Targets 2009, 13:823-837.
• [56]McDermott SP, Wicha MS: Targeting breast cancer stem cells. Mol Oncol 2010, 4:404-419.
• [57]DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL: Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011, 17:1514-1520.
• [58]Vici P, Sergi D, Pizzuti L, Vincenzoni C, Baiocco E, Mancini E, Lopez M, Vizza E, Lauro LD: Biological progression of breast cancer and clinical implications. Clin Ter 2011, 162:297-299.
• [59]Malaret GE, Aliaga P: Metastatic disease to the heart. Cancer 1968, 22:457-466.
• [60]Perchinsky MJ, Lichtenstein SV, Tyers GF: Primary cardiac tumors: forty years’ experience with 71 patients. Cancer 1997, 79:1809-1815.
• [61]Vaitkus PT, Hermann HC, LeWinter MM: Treatment of malignant pericardial effusion. JAMA 1994, 272:59-64.
• [62]Slater SR, Kroop IG, Zuckerman S: Constrictive pericarditis caused by solitary metastatic carcinosis of the pericardium and complicated by radiation fibrosis of mediastinum. Am Heart J 1952, 43:401-412.
• [63]Lamberta F, Nareff MJ, Schwab J: Metastatic carcinoma of pericardium. Dis Chest 1951, 19:528-536.
• [64]Wolver S, Franklin RW, Abbate A: ST-segment elevation and new right-bundle branch block: broadening the differential diagnosis. Int J Cardiol 2007, 114:247-248.
• [65]Cates CU, Virmani R, Vaughn WK, Robertson RM: Electrocardiographic markers of cardiac metastasis. Am Heart J 1986, 112:1297-1303.
• [66]Rosenbaum F, Johnston FD, Alzamora VV: Persistenit displacement of RS-T segmeat in case of metastatic tumor of heart. Am Heart J 1944, 27:667-675.
• [67]Siegel ML, Young AM: Electrocardiographic findings in tumors of heart, with report of case. Am Heart J 1933, 8:682-690.
• [68]Hanfling SM: Metastatic cancer to the heart: review of the literature and report of 127 cases. Circulation 1960, 22:474-483.
• [69]Sun JP, Asher CR, Xu Y, Huang V, Griffin BP, Stewart WJ, Novick AC, Thomas JD: Inferior vena caval masses identified by echocardiography. Am J Cardiol 1999, 84:613-615.
• [70]Hamada S, Nishimura T, Hayashida K, Uehara T: Intracardiac malignant lymphoma detected by Gallium-67 Citrate and Thallium-201 Chloride. J Nuc Med 1988, 29:1868-1870.
• [71]Johnson TRC, Becker CR, Wintersperger BJ, Herzog P, Lenhard MS, Reiser MF: Detection of cardiac metastasis by positron-emission tomography-computed tomography. Circulation 2005, 112:61-62.
• [72]Pichler BJ, Kolb A, Nägele T, Schlemmer HP: PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med 2010, 51:333-336.
• [73]Houck RC, Cooke JE, Gill EA: Live 3D echocardiography: a replacement for traditional 2D echocardiography? AJR 2006, 187:1092-1106.
• [74]Catton C: The management of malignant cardiac tumours: clinical considerations. Semin Diagn Pathol 2008, 25:69-75.
• [75]Ravikumar TS, Topulos GP, Anderson RW, Grage TB: Surgical resection for isolated cardiac metastases. Arch Surg 1983, 118:117-120.
• [76]Poole GV, Meredith JW, Breyer RH, Mills SA: Surgical implications in malignant cardiac disease. Ann Thorac Surg 1983, 36:484-491.
• [77]Ohnishi M, Niwayama H, Miyazawa Y, Kondo N, Imai H, Nishimoto Y, Morooka N, Watanabe S, Masuda Y, Inagaki Y: Echocardiography in patients with malignant metastatic neoplasms of the heart and great vessels. J Cardiol 1990, 20:377-384.
• [78]Carrel T, Erdös G, Eberle B, Englberger L, Pfammatter JP, Schmidli J, Kadner A, Stalder M: Surgical treatment of cardiac tumours - an overview and presentation of interesting cases. Cardiovascular Medicine 2011, 14:242-257.